JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

AZN

73.59

-1.31%↓

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

AZN

73.59

-1.31%↓

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

AZN

73.59

-1.31%↓

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

AZN

73.59

-1.31%↓

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

AZN

73.59

-1.31%↓

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

Novartis AG

Затворен

116.79 0.8

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

116.52

Максимум

116.9

Ключови измерители

By Trading Economics

Приходи

418M

4B

Продажби

660M

14B

P/E

Средно за сектора

16.809

34.393

EPS

2.42

Дивидентна доходност

3.46

Марж на печалбата

28.18

Служители

75,883

EBITDA

-5.8B

4.9M

Препоръки

By TipRanks

Препоръки

Неутрален

12-месечна прогноза

+5.92% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

3.46%

2.54%

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-11B

228B

Предишно отваряне

115.99

Предишно затваряне

116.79

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

Novartis AG Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

7.08.2025 г., 05:47 ч. UTC

Придобивния, сливания и поглъщания

Novartis Makes Takeover Approach for Avidity Biosciences, FT Says, Citing Sources

17.07.2025 г., 14:26 ч. UTC

Печалби

Novartis Launches Buyback of Up to $10 Billion, Lifts Profit Outlook -- 2nd Update

17.07.2025 г., 06:49 ч. UTC

Печалби

Novartis Launches Buyback of Up to $10 Billion, Lifts Profit Outlook -- Update

17.07.2025 г., 05:41 ч. UTC

Печалби

Novartis Lifts Profit Outlook After Growth in Sales, Earnings

8.08.2025 г., 11:26 ч. UTC

Пазарно говорене

Novartis Is Getting Closer to Midterm Targets -- Market Talk

8.08.2025 г., 11:07 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Novartis Has Room to Accelerate Dealmaking -- Market Talk

8.08.2025 г., 10:51 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Novartis's Midterm Prospects Look Better Than Roche's -- Market Talk

5.08.2025 г., 10:40 ч. UTC

Пазарно говорене

Roche, Novartis Face Limited Tariff Headwinds for Now -- Market Talk

17.07.2025 г., 11:36 ч. UTC

Пазарно говорене

Novartis CEO Urges Europe to Reform Drug-Pricing System -- Market Talk

17.07.2025 г., 11:26 ч. UTC

Пазарно говорене

Novartis CEO Confident on Midterm Plan to Mitigate U.S. Tariff Hit -- Market Talk

17.07.2025 г., 07:14 ч. UTC

Пазарно говорене

Retirement of Well-Regarded Executive a Loss for Novartis -- Market Talk

17.07.2025 г., 07:02 ч. UTC

Пазарно говорене
Печалби

Novartis's Results Look Impressive -- Market Talk

17.07.2025 г., 05:09 ч. UTC

Печалби

Novartis 2Q Sales Grew 11% at Constant Currency

17.07.2025 г., 05:08 ч. UTC

Печалби

Novartis: Kirsch Will Continue as CFO, Member of Executive Committee Until March 2026

17.07.2025 г., 05:06 ч. UTC

Печалби

Novartis: Mehta's Appointment Is Effective March 2026

17.07.2025 г., 05:05 ч. UTC

Печалби

Novartis: Harry Kirsch Retires After 22 Years With Company

17.07.2025 г., 05:05 ч. UTC

Печалби

Novartis Names Mukul Mehta as CFO

17.07.2025 г., 05:04 ч. UTC

Печалби

Analysts Saw Novartis 2Q Net Profit at $3.815B

17.07.2025 г., 05:04 ч. UTC

Печалби

Analysts Saw Novartis 2Q Core Operating Profit at $5.75B

17.07.2025 г., 05:04 ч. UTC

Печалби

Analysts Saw Novartis 2Q Sales at $14.17B

17.07.2025 г., 05:04 ч. UTC

Печалби

Novartis 2Q Core Operating Profit $5.925B

17.07.2025 г., 05:04 ч. UTC

Печалби

Novartis 2Q Oper Pft $4.86B

17.07.2025 г., 05:03 ч. UTC

Печалби

Novartis 2Q Sales $14.05B

17.07.2025 г., 05:01 ч. UTC

Печалби

Novartis: Buyback to Be Completed by End of 2027

17.07.2025 г., 05:01 ч. UTC

Печалби

Novartis Starting Buyback of Up to $10B

17.07.2025 г., 05:01 ч. UTC

Печалби

Novartis Backs 2025 Sales View

17.07.2025 г., 05:01 ч. UTC

Печалби

Novartis Had Guided for Low Double-Digit Growth in Core Operating Profit at Constant Currency

17.07.2025 г., 05:01 ч. UTC

Печалби

Novartis Expects 2025 Core Operating Profit to Grow by Low Teens at Constant Currency

17.07.2025 г., 05:00 ч. UTC

Печалби

Novartis Raises 2025 Earnings View

17.07.2025 г., 05:00 ч. UTC

Печалби

Novartis AG 2Q Adj EPS $2.42

Сравнение с други в отрасъла

Ценова промяна

Novartis AG Прогноза

Ценова цел

By TipRanks

5.92% нагоре

12-месечна прогноза

Среден 122.78 USD  5.92%

Висок 137.561 USD

Нисък 108 USD

Според 3 анализатори от Wall Street, предложили 12-месечна ценова цел за Novartis AG през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

3 ratings

0

Купи

3

Задържане

0

Продай

Техническа оценка

By Trading Central

N/A / 112.63Подкрепа & съпротива

Краткосрочен план

Bearish Evidence

Средносрочен план

Weak Bullish Evidence

Дългосрочен план

Strong Bullish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Novartis AG

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. The company has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. It also has a research collaboration and license agreement with Schrödinger, Inc. to identify and develop various therapeutic candidates; and a strategic collaboration with Vyriad, Inc. for the discovery and development for vivo chimeric antigen receptor T-cell therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.